{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T11:17:11Z","timestamp":1722943031501},"reference-count":21,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2022,1,25]]},"DOI":"10.1253\/circj.cj-21-0247","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T18:09:03Z","timestamp":1626372543000},"page":"280-286","source":"Crossref","is-referenced-by-count":2,"title":["Catheter Ablation Energy Sources and Myocardial Injury and Coagulation Biomarkers During Uninterrupted Periprocedural Edoxaban Use\u3000\u2015 A Subanalysis of KYU-RABLE \u2015"],"prefix":"10.1253","volume":"86","author":[{"given":"Tetsuji","family":"Shinohara","sequence":"first","affiliation":[{"name":"Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Mukai","sequence":"additional","affiliation":[{"name":"Cardiology Division, Japanese Red Cross Fukuoka Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Medical Science Department, Daiichi Sankyo Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Medical Science Department, Daiichi Sankyo Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takita","sequence":"additional","affiliation":[{"name":"Data Intelligence Department, Daiichi Sankyo Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Origasa","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Clinical Epidemiology, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Okumura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the KYU-RABLE Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS\/EHRA\/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. <i>Heart Rhythm<\/i> 2012; 9: 632\u2013696.e21."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hindricks G, Sepehri Shamloo A, Lenarczyk R, Kalarus Z, Arya A, Kircher S, et al. Catheter ablation of atrial fibrillation: Current status, techniques, outcomes and challenges. <i>Kardiol Pol<\/i> 2018; 76: 1680\u20131686.","DOI":"10.5603\/KP.a2018.0216"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Antoli\u010d B, Pernat A, Cviji\u0107 M, \u017di\u017eek D, Jan M, \u0160inkovec M. Radiofrequency catheter ablation versus balloon cryoablation of atrial fibrillation: Markers of myocardial damage, inflammation, and thrombogenesis. <i>Wien Klin Wochenschr<\/i> 2016; 128: 480\u2013487.","DOI":"10.1007\/s00508-016-1002-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hisazaki K, Hasegawa K, Kaseno K, Miyazaki S, Amaya N, Shiomi Y, et al. Endothelial damage and thromboembolic risk after pulmonary vein isolation using the latest ablation technologies: A comparison of the second-generation cryoballoon vs. contact force-sensing radiofrequency ablation. <i>Heart Vessels<\/i> 2019; 34: 509\u2013516.","DOI":"10.1007\/s00380-018-1257-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. K\u0131z\u0131l\u0131rmak F, Gokdeniz T, Gunes HM, Demir GG, Cakal B, Guler GB, et al. Myocardial injury biomarkers after radiofrequency catheter and cryoballoon ablation for atrial fibrillation and their impact on recurrence. <i>Kardiol Pol<\/i> 2017; 75: 126\u2013134.","DOI":"10.5603\/KP.a2016.0089"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Malmborg H, Christersson C, L\u00f6nnerholm S, Blomstr\u00f6m-Lundqvist C. Comparison of effects on coagulation and inflammatory markers using a duty-cycled bipolar and unipolar radiofrequency pulmonary vein ablation catheter vs. a cryoballoon catheter for pulmonary vein isolation. <i>Europace<\/i> 2013; 15: 798\u2013804.","DOI":"10.1093\/europace\/eus411"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Cardoso R, Knijnik L, Bhonsale A, Miller J, Nasi G, Rivera M, et al. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. <i>Heart Rhythm<\/i> 2018; 15: 107\u2013115.","DOI":"10.1016\/j.hrthm.2017.09.011"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Basu-Ray I, Khanra D, Kup\u00f3 P, Bunch J, Theus SA, Mukherjee A, et al. Outcomes of uninterrupted vs interrupted periprocedural direct oral anticoagulants in atrial fibrillation ablation: A meta-analysis. <i>J Arrhythm<\/i> 2021; 37: 384\u2013393.","DOI":"10.1002\/joa3.12507"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hohnloser SH, Camm J, Cappato R, Diener HC, Heidb\u00fcchel H, Mont L, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: The ELIMINATE-AF trial. <i>Eur Heart J<\/i> 2019; 40: 3013\u20133021.","DOI":"10.1093\/eurheartj\/ehz190"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Takahashi N, Mukai Y, Kimura T, Yamaguchi K, Matsumoto T, Origasa H, et al. Efficacy and safety of uninterrupted periprocedural edoxaban in patients undergoing catheter ablation for atrial fibrillation: The prospective KYU-RABLE study. <i>Circ J<\/i> 2019; 83: 2017\u20132024.","DOI":"10.1253\/circj.CJ-19-0535"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shinohara T, Takahashi N, Mukai Y, Kimura T, Yamaguchi K, Takita A, et al. Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU-RABLE. <i>J Arrhythm<\/i> 2021; 37: 70\u201378.","DOI":"10.1002\/joa3.12490"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment. <i>Circ J<\/i> 2015; 79: 1486\u20131495.","DOI":"10.1253\/circj.CJ-14-0942"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Andrade JG, Dubuc M, Guerra PG, Macle L, Mond\u00e9sert B, Rivard L, et al. The biophysics and biomechanics of cryoballoon ablation. <i>Pacing Clin Electrophysiol<\/i> 2012; 35: 1162\u20131168.","DOI":"10.1111\/j.1540-8159.2012.03436.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Khairy P, Chauvet P, Lehmann J, Lambert J, Macle L, Tanguay JF, et al. Lower incidence of thrombus formation with cryoenergy versus radiofrequency catheter ablation. <i>Circulation<\/i> 2003; 107: 2045\u20132050.","DOI":"10.1161\/01.CIR.0000058706.82623.A1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ang R, Domenichini G, Finlay MC, Schilling RJ, Hunter RJ. The hot and the cold: Radiofrequency versus cryoballoon ablation for atrial fibrillation. <i>Curr Cardiol Rep<\/i> 2015; 17: 631.","DOI":"10.1007\/s11886-015-0631-7"},{"key":"16","unstructured":"16. Japanese Circulation Society, Japanese Heart Rhythm Society. 2018 JCS\/JHRS guideline on non-pharmacotherapy of cardiac arrhythmias [in Japanese]. 2019. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2018\/07\/JCS2018_kurita_nogami.pdf (accessed March 2, 2021)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hoffman M, Goldstein JN, Levy JH. The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: A review. <i>Int J Emerg Med<\/i> 2018; 11: 55.","DOI":"10.1186\/s12245-018-0215-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Okishige K, Hirao T, Oda A, Shigeta T, Nakamura RA, Yoshida H, et al. Blood coagulation status during cryofreezing ablation and effects of the direct anticoagulants dabigatran and edoxaban. <i>Int Heart J<\/i> 2020; 61: 249\u2013253.","DOI":"10.1536\/ihj.19-450"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yanagisawa S, Inden Y, Fujii A, Sakamoto Y, Tomomatsu T, Mamiya K, et al. Prothrombotic responses after catheter ablation for atrial fibrillation during uninterrupted oral anticoagulant agent administration. <i>JACC Clin Electrophysiol<\/i> 2019; 5: 1418\u20131427.","DOI":"10.1016\/j.jacep.2019.09.002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J, et al. Elevated levels of prothrombin fragment 1+2 indicate high risk of thrombosis. <i>Clin Appl Thromb Hemost<\/i> 2008; 14: 279\u2013285.","DOI":"10.1177\/1076029607309176"},{"key":"21","unstructured":"21. Japanese Heart Rhythm Society. Report on the results of all eight surveys from the registration study on catheter ablation for atrial fibrillation (J-CARAF Registry) [in Japanese]. http:\/\/new.jhrs.or.jp\/pdf\/case-registy\/j-caraf202002_01.pdf (accessed March 2, 2021)."}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/86\/2\/86_CJ-21-0247\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T22:52:31Z","timestamp":1643410351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/86\/2\/86_CJ-21-0247\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-21-0247","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"type":"print","value":"1346-9843"},{"type":"electronic","value":"1347-4820"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"article-number":"CJ-21-0247"}}